AlloVir Faces Delisting Risk, Considers Reverse Split to Comply
Company Announcements

AlloVir Faces Delisting Risk, Considers Reverse Split to Comply

AlloVir (ALVR) has released an update.

AlloVir, Inc. has been notified by Nasdaq that its stock price fell below the $1.00 minimum bid requirement for 30 days, putting it at risk of delisting. The company remains listed and has 180 days to rectify the situation by maintaining a bid price of $1.00 or more for ten consecutive days. AlloVir is exploring options, including a potential reverse stock split, to regain compliance and avoid delisting from the Nasdaq Global Select Market.

For further insights into ALVR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAlloVir and Kalaris Merge to Advance Retinal Therapies
TheFlyAlloVir to combine with Kalaris Therapeutics in all-stock transaction
TipRanks Auto-Generated NewsdeskAlloVir Finalizes $7 Million Lease Termination Deal
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App